Rates of diagnosis and treatment are low, so there is need for diagnostic tests and biomarkers for classification and ...

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

In a major new finding almost a decade in the making, researchers at Harvard Medical School say they’ve found a key that may ...

New drugs show promise, and research finds value in vaccines, antivirals, exercise and probiotics.

This research offers hope. By finding brain diseases earlier, we might be able to slow them down or manage them better. If ...

The study included 2,469 participants from France, Japan and Finland who ... Study co-author Jenni Lehtisalo, a research fellow at the Finnish Institute for Health and Welfare, said the main takeaway ...

More than 82 million people could be living with dementia by 2030,1 the majority in low-income and middle-income countries where access to specialist care and diagnostic tests is highly variable.

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study. In the high-dose cohort from the ongoing Phase Ib/IIa Brainshuttle AD ...

This is the moment to spend more money on research, not less. Right now, all over the world, researchers are collecting data about Alzheimer’s disease.

NIH funding for research on Alzheimer’s and other forms of dementia has risen from $562 million in 2014 to $3.9 billion in 2024.